‘I’m happy to have this matter behind us,’ says company CEO
PALM DESERT, Calif., July 10, 2022 /PRNewswire-PRWeb/ — NOVA OCULUS PARTNERS, LLC has reached a settlement with the Securities and Exchange Commission (SEC) that ends the SEC’s enforcement action against the company. The settlement (Case # 5:18-cv-00701-FLA-SPx; U.S. District Court for the Central District of California) stipulates the company will not pay any monetary penalties and agrees only to an injunction not to violate securities laws. Moreover, the company and its officers neither admit nor deny having violated any securities laws.
Company CEO Walter O’Rourke said he is pleased with this resolution of the SEC action. “I’m happy to have this matter finally behind us,” he said. “This settlement allows the company and its investors to move on. There are a lot of exciting new developments in store.”
ABOUT NOVA OCULUS
NOVA OCULUS is the name of the pioneering new medical device engineered and developed to treat the dry form of Age-Related Macular Degeneration—and for the company of innovative people that created it.
The Nova Oculus device holds the potential to revolutionize the treatment protocols for dry AMD and offer hope to millions of North Americans who are going blind without it. Dry AMD is an affliction without a cure. Yet independent assessments of a recent clinical investigative trial in Vancouver proved the company’s microcurrent electro-therapy technology was successful in mitigating AMD’s symptoms in those patients treated with the device.
The Nova Oculus device has been certified as complying with the quality management standard set by the International Organization of Standardization (ISO) and the electrical safety standard set by the International Electrotechnical Commission (IEC). These certifications make possible future global regulatory approvals for Nova Oculus.
Media Contact
Walter O’Rourke, Nova Oculus Partners, LLC, 1 647-204-3477, [email protected]
SOURCE Nova Oculus Partners, LLC
